Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia

References

• Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70. doi:10.1182/blood-2015-07-604546
   PubMed Web of Science ®Google Scholar
• Piemontese S, Boumendil A, Labopin M, et al. Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. J Hematol Oncol. 2019;12(1):68. doi:10.1186/s13045-019-0751-4
   PubMedGoogle Scholar
• Jan M, Leventhal MJ, Morgan EA, et al. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019;3(14):2199–2204. doi:10.1182/bloodadvances.2019000445
   PubMed Web of Science ®Google Scholar
• Schmid C, de Wreede LC, van Biezen A, et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Haematologica. 2018;103(2):237–245. doi:10.3324/haematol.2017.168716
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4(9):1245–1253. doi:10.1001/jamaoncol.2018.2091
   PubMed Web of Science ®Google Scholar
• Seymour JF, Döhner H, Butrym A, et al. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017;17(1):852. doi:10.1186/s12885-017-3803-6
   PubMedGoogle Scholar
• Zeidan AM, Wang R, Wang X, et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192–2201. doi:10.1182/bloodadvances.2020001779
   PubMed Web of Science ®Google Scholar
• Craddock C, Labopin M, Robin M, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101(7):879–883. doi:10.3324/haematol.2015.140996
   PubMed Web of Science ®Google Scholar
• Schroeder T, Fröbel J, Cadeddu RP, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27(9):1910–1913. doi:10.1038/leu.2013.64
   PubMed Web of Science ®Google Scholar
• Antar AI, Otrock ZK, Abou Dalle I, et al. Pharmacologic therapies to prevent relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Front Oncol. 2020;10:596134. doi:10.3389/fonc.2020.596134
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38(36):4249–4259. doi:10.1200/JCO.19.03277
   PubMed Web of Science ®Google Scholar
• Wattebled KJ, Drumez E, Coiteux V, et al. Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2022;101(6):1321–1331. doi:10.1007/s00277-022-04821-y
   PubMed Web of Science ®Google Scholar
• Zhang R, Lu X, Wang H, et al. Idarubicin-intensified hematopoietic cell transplantation improves relapse and survival of high-risk acute leukemia patients with minimal residual disease. Biol Blood Marrow Transplant. 2019;25(1):47–55. doi:10.1016/j.bbmt.2018.07.021
   PubMed Web of Science ®Google Scholar
• Zhang R, Shi W, Wang HF, et al. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplant. 2017;52(9):1253–1260. doi:10.1038/bmt.2017.100
   PubMed Web of Science ®Google Scholar
• Fang J, Zhang R, Wang H, et al. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective comparative study. Leuk Res. 2019;81:107–168. doi:10.1016/j.leukres.2016.04.014
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(9):1079–1109. doi:10.6004/jnccn.2021.0042
   PubMedGoogle Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. doi:10.1016/j.bbmt.2014.12.001
   PubMed Web of Science ®Google Scholar
• Pasvolsky O, Shimony S, Yeshurun M, et al. Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. Acta Oncol. 2021;60(10):1335–1341. doi:10.1080/0284186X.2021.1955969
   PubMed Web of Science ®Google Scholar
• Lee CJ, Shiraz P, Muffly L. Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leuk Lymphoma. 2017;58(3):516–527. doi:10.1080/10428194.2016.1205744
   PubMed Web of Science ®Google Scholar
• Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):4. doi:10.1186/s13045-020-01017-7
   PubMed Web of Science ®Google Scholar
• Sorrentino VG, Thota S, Gonzalez EA, et al. Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia. Pharmaceuticals. 2021;14(7):641. doi:10.3390/ph14070641
   Web of Science ®Google Scholar
• Stomper J, Rotondo JC, Greve G, et al. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873–1889. doi:10.1038/s41375-021-01218-0
   PubMed Web of Science ®Google Scholar
• Touzart A, Mayakonda A, Smith C, et al. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Sci Transl Med. 2021;13(595):eabc4834. doi:10.1126/scitranslmed.abc4834
   PubMed Web of Science ®Google Scholar
• Christopher MJ, Petti AA, Rettig MP, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379(24):2330–2341. doi:10.1056/NEJMoa1808777
   PubMed Web of Science ®Google Scholar
• Vasu S, He S, Cheney C, et al. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. 2016;127(23):2879–2889. doi:10.1182/blood-2015-11-680546
   PubMed Web of Science ®Google Scholar
• Tsirogianni M, Grigoriou E, Kapsimalli V, et al. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. Leuk Lymphoma. 2019;60(10):2457–2463. doi:10.1080/10428194.2019.1581935
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–3369. doi:10.1182/blood-2011-09-377044
   PubMed Web of Science ®Google Scholar
• Baek DW, Kim J, Cho HJ, et al. Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation. Expert Rev Hematol. 2020;13(9):959–969. doi:10.1080/17474086.2020.1804355
   PubMed Web of Science ®Google Scholar
• Pusic I, Choi J, Fiala MA, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21(10):1761–1769. doi:10.1016/j.bbmt.2015.05.026
   PubMed Web of Science ®Google Scholar
• de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420–5431. doi:10.1002/cncr.25500
   PubMed Web of Science ®Google Scholar
• Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580–5588. doi:10.1182/bloodadvances.2020002544
   PubMed Web of Science ®Google Scholar
• Xie M, Jiang Q, Xie Y. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Clin Lymphoma Myeloma Leuk. 2015;15(1):22–28. doi:10.1016/j.clml.2014.04.010
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017;130(13):1514–1522. doi:10.1182/blood-2017-06-788497
   PubMed Web of Science ®Google Scholar
• Liu W, Zhou Z, Chen L, et al. Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: a network meta-analysis. Clin Lymphoma Myeloma Leuk. 2021;21(6):e530–e544. doi:10.1016/j.clml.2021.01.024
   PubMed Web of Science ®Google Scholar
• Chatterton Z, Morenos L, Mechinaud F, et al. Epigenetic deregulation in pediatric acute lymphoblastic leukemia. Epigenetics. 2014;9(3):459–467. doi:10.4161/epi.27585
   PubMed Web of Science ®Google Scholar
• Shen L, Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003;101(10):4131–4136. doi:10.1182/blood-2002-08-2466
   PubMed Web of Science ®Google Scholar
• Holling TM, Schooten E, Langerak AW, et al. Regulation of MHC class II expression in human T-cell malignancies. Blood. 2004;103(4):1438–1444. doi:10.1182/blood-2003-05-1491
   PubMed Web of Science ®Google Scholar